Dataset Information


Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.

ABSTRACT: Currently approved therapies for age-related macular degeneration (AMD) are inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of neovascular AMD (nAMD). Intravitreal injections of anti-VEGF drugs have shown dramatic visual benefits for AMD patients. However, a significant portion of AMD patients exhibit an incomplete response to therapy and, over the extended management course, can lose vision, with the formation of submacular fibrosis as one risk factor. We investigated a novel target for AMD treatments, fibroblast growth factor 2 (FGF2), which has been implicated in the pathophysiology of both angiogenesis and fibrosis in a variety of tissue and organ systems. The anti-FGF2 aptamer, RBM-007, was examined for treatment of nAMD in animal models. In in vivo studies conducted in mice and rats, RBM-007 was able to inhibit FGF2-induced angiogenesis, laser-induced choroidal neovascularization (CNV), and CNV with fibrosis. Pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and relatively long-lasting profiles that are superior to other approved anti-VEGF drugs. The anti-angiogenic and anti-scarring dual action of RBM-007 holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD.


PROVIDER: S-EPMC6716068 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6835305 | BioStudies
2020-01-01 | S-EPMC7442859 | BioStudies
2020-01-01 | S-EPMC6987119 | BioStudies
1000-01-01 | S-EPMC4648089 | BioStudies
2020-01-01 | S-EPMC7146894 | BioStudies
2018-01-01 | S-EPMC5800432 | BioStudies
2018-01-01 | S-EPMC6079038 | BioStudies
2018-01-01 | S-EPMC5786856 | BioStudies
2018-01-01 | S-EPMC6306402 | BioStudies
2016-01-01 | S-EPMC4807815 | BioStudies